| Symbol | CABA |
|---|---|
| Name | CABALETTA BIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 2929 ARCH STREET,SUITE 600, PHILADELPHIA, Pennsylvania, 19104, United States |
| Telephone | +1 267 759-3100 |
| Fax | — |
| — | |
| Website | https://www.cabalettabio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001759138 |
| Description | Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAAR, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CAAR T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T cell technology that is marketed for the treatment of B cell cancers. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Cabaletta Bio, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003687 <b>Size:</b> 10 KB
Read moreNew Form SCHEDULE 13G/A - Cabaletta Bio, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-350333 <b>Size:</b> 9 KB
Read moreCabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Read moreCabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Read moreNew Form SCHEDULE 13G/A - Cabaletta Bio, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0000919574-26-004972 <b>Size:</b> 13 KB
Read moreNew Form SCHEDULE 13G - Cabaletta Bio, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001374170-26-000058 <b>Size:</b> 7 KB
Read moreNew Form SCHEDULE 13G - Cabaletta Bio, Inc. <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0002100119-26-001326 <b>Size:</b> 7 KB
Read moreNew Form SCHEDULE 13G/A - Cabaletta Bio, Inc. <b>Filed:</b> 2026-07-23 <b>AccNo:</b> 0001104659-26-086361 <b>Size:</b> 15 KB
Read moreTomasello Shawn 🟢 acquired 22.0K shares (1 derivative) of Cabaletta Bio, Inc. (CABA) at $3.22 Transaction Date: Jun 09, 2026 | Filing ID: 266239
Read more